Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Revenue from External Customer [Line Items]
Revenues	[1]	$ 12,028	$ 13,118
Biopharma, Upjohn And Consumer Healthcare Segments [Member]
Revenue from External Customer [Line Items]
Revenues		12,028	13,118
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		1,382	1,090
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	288	179
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,407	1,237
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		10,007	9,045
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	2,332	2,137
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,300	1,011
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	270	273
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	152	168
Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	69	67
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	60	60
Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	480	559
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,435	1,961
Oncology [Member] | Biopharma [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,248	1,133
Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		209	168
Oncology [Member] | Biopharma [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		205	232
Oncology [Member] | Biopharma [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		169	73
Oncology [Member] | Biopharma [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		149	123
Oncology [Member] | Biopharma [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		100	80
Oncology [Member] | Biopharma [Member] | Retacrit [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	89	31
Oncology [Member] | Biopharma [Member] | Braftovi [Member]
Revenue from External Customer [Line Items]
Revenues		37	0
Oncology [Member] | Biopharma [Member] | Mektovi [Member]
Revenue from External Customer [Line Items]
Revenues		37	0
Oncology [Member] | Biopharma [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		192	122
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	2,012	1,827
Hospital [Member] | Biopharma [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	187	177
Hospital [Member] | Biopharma [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	138	104
Hospital [Member] | Biopharma [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	129	120
Hospital [Member] | Biopharma [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	74	85
Hospital [Member] | Biopharma [Member] | Panzyga [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	74	17
Hospital [Member] | Biopharma [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	70	64
Hospital [Member] | Biopharma [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	59	60
Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5],[6]	152	176
Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	444	405
Hospital [Member] | Biopharma [Member] | All other Hospital [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	684	620
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,611	1,612
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,450	1,486
Vaccines [Member] | Biopharma [Member] | Nimenrix [Member]
Revenue from External Customer [Line Items]
Revenues		75	50
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		86	77
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		978	1,037
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		451	423
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		347	451
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	158	138
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All other I & I [Member]
Revenue from External Customer [Line Items]
Revenues		22	25
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		639	470
Rare Disease [Member] | Biopharma [Member] | Vyndaqel/Vyndamax [Member]
Revenue from External Customer [Line Items]
Revenues		231	41
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		121	125
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		103	107
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		89	106
Rare Disease [Member] | Biopharma [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		64	59
Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		31	31
Upjohn [Member] | Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	2,022	3,214
Upjohn [Member] | Upjohn [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	405	622
Upjohn [Member] | Upjohn [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	357	1,186
Upjohn [Member] | Upjohn [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	197	300
Upjohn [Member] | Upjohn [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	156	174
Upjohn [Member] | Upjohn [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	127	145
Upjohn [Member] | Upjohn [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	78	69
Upjohn [Member] | Upjohn [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	77	77
Upjohn [Member] | Upjohn [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	72	56
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	61	62
Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	492	523
Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	$ 0	$ 858

[1] Amounts may not add due to rounding.

[2] Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.

[3] Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

[4] Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.

[5] Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne^(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.

[6] Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.

[7] On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B.